Sterling builds up its API capacity with big buy of Novartis campus in Ireland
A massive 111-acre manufacturing site in Ireland owned by Novartis has been acquired by Sterling Pharma Solutions, further bolstering its active pharmaceutical ingredient (API) capacity and providing expanded access for customers.
The site is in Ringaskiddy, roughly 30 minutes from Cork, Ireland, and right now manufactures APIs in three different buildings on the campus, and has the capacity to scale-up operations and space for R&D. The deal will include a supply agreement between Sterling and Novartis. The workforce will transition to Sterling employees once the deal closes, the company said. Chief Commercial Officer Andrew Henderson said in an email to Endpoints News that the site’s focus in small molecule service and its similarity to capabilities already-owned sites in Northumberland, UK and Wisconsin all made the deal more attractive to his team.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.